File Download
 
 
Supplementary

Conference Paper: An investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleAn investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma
 
AuthorsWong, LLY
Lam, IPY
Wong, TYN
Lai, WL
Zhou, Y
Hung, WY
Ching, YP
 
Issue Date2012
 
PublisherAmerican Association for Cancer Research.
 
CitationThe 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012. [How to Cite?]
 
AbstractBACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ...
 
DescriptionPoster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429
 
DC FieldValue
dc.contributor.authorWong, LLY
 
dc.contributor.authorLam, IPY
 
dc.contributor.authorWong, TYN
 
dc.contributor.authorLai, WL
 
dc.contributor.authorZhou, Y
 
dc.contributor.authorHung, WY
 
dc.contributor.authorChing, YP
 
dc.date.accessioned2012-06-22T06:29:49Z
 
dc.date.available2012-06-22T06:29:49Z
 
dc.date.issued2012
 
dc.description.abstractBACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ...
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionPoster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429
 
dc.description.otherThe 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012.
 
dc.identifier.citationThe 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012. [How to Cite?]
 
dc.identifier.hkuros199949
 
dc.identifier.urihttp://hdl.handle.net/10722/149198
 
dc.languageeng
 
dc.publisherAmerican Association for Cancer Research.
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAnnual Meeting of the American Association for Cancer Research
 
dc.titleAn investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, LLY</contributor.author>
<contributor.author>Lam, IPY</contributor.author>
<contributor.author>Wong, TYN</contributor.author>
<contributor.author>Lai, WL</contributor.author>
<contributor.author>Zhou, Y</contributor.author>
<contributor.author>Hung, WY</contributor.author>
<contributor.author>Ching, YP</contributor.author>
<date.accessioned>2012-06-22T06:29:49Z</date.accessioned>
<date.available>2012-06-22T06:29:49Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>The 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012.</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/149198</identifier.uri>
<description>Poster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429</description>
<description.abstract>BACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ...</description.abstract>
<language>eng</language>
<publisher>American Association for Cancer Research.</publisher>
<relation.ispartof>Annual Meeting of the American Association for Cancer Research</relation.ispartof>
<title>An investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma</title>
<type>Conference_Paper</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.hkuros>199949</identifier.hkuros>
<publisher.place>United States</publisher.place>
<description.other>The 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012.</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/149198/1/re01.htm</bitstream.url>
</item>